PT Kimia Farma TbkISX:KAEF -2.15%56 ROE % is 16.64% as of Mar. 2026, which is 166300% above its 10-year median of 0.01. GuruFocus rates ISX:KAEF with a GF Score™ of 56/100 and a GF Value™ of Rp581.98 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 113 Medical Distribution companies, PT Kimia Farma Tbk ranks worse than 83.19% on this metric.
The historical rank and industry rank for PT Kimia Farma Tbk's ROE % or its related term are showing as below:
ISX:KAEF'
s ROE % Range Over the Past 10 Years
Min: -43.97 Med: 0.01 Max: 13.65
Current: -7.73
During the past 13 years, PT Kimia Farma Tbk's highest ROE % was 13.65%. The lowest was -43.97%. And the median was 0.01%.
ISX:KAEF's ROE % is ranked worse than 83.19% of 113
companies
in the Medical Distribution industry
Industry Median: 7.1
vs ISX:KAEF: -7.73
PT Kimia Farma Tbk (ISX:KAEF) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
PT Kimia Farma Tbk ROE % Related Terms
PT Kimia Farma Tbk ROE % Historical Data
* Premium members only.
The historical data trend for PT Kimia Farma Tbk's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, PT Kimia Farma Tbk's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kimia Farma Tbk ROE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Kimia Farma Tbk's ROE % distribution charts can be found below:
* The bar in red indicates where PT Kimia Farma Tbk's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
PT Kimia Farma Tbk (ISX:KAEF) has a ROE % of 16.64% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on PT Kimia Farma Tbk and its competitors. This is 166300% above median its historical median of 0.01. According to the industry distribution chart, PT Kimia Farma Tbk ranks #94 out of 113 companies in the Medical Distribution industry, placing it in the top 83.2%.
Is PT Kimia Farma Tbk's ROE % too high?
PT Kimia Farma Tbk's current ROE % of 16.64% is 166300% above median its 10-year median of 0.01. The Medical Distribution industry median ROE % is 7.10. PT Kimia Farma Tbk's value of 16.64% is 134.4% above this industry median. Based on the distribution chart, PT Kimia Farma Tbk ranks #94 out of 113 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, PT Kimia Farma Tbk has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kimia Farma Tbk's ROE % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Kimia Farma Tbk ranks #94 out of 113 companies for ROE %. This places PT Kimia Farma Tbk in the lower half of its industry. The industry median ROE % is 7.10. PT Kimia Farma Tbk's value of 16.64% is 134.4% above this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 7.10, PT Kimia Farma Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Distribution company?
The median ROE % among Medical Distribution companies is 7.10, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kimia Farma Tbk's current ROE % of 16.64% is 134.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on PT Kimia Farma Tbk and its competitors. For the Medical Distribution industry, the median ROE % is 7.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kimia Farma Tbk's current ROE % is 16.64%, which is 166300% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kimia Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kimia Farma Tbk (ISX:KAEF) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp581.98, compared to a current price of Rp456.00 — trading 21.6% below its estimated fair value. The current ROE % is 16.64%, which is 166300% above median its 10-year median of 0.01 and 134.4% above the Medical Distribution industry median of 7.10. PT Kimia Farma Tbk's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For PT Kimia Farma Tbk (ISX:KAEF), the current ROE % is 16.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kimia Farma Tbk (ISX:KAEF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kimia Farma Tbk stock appears to be undervalued.
The current stock price of Rp456.00 is trading 21.6% below its estimated GF Value™ of Rp581.98.
GuruFocus considers PT Kimia Farma Tbk to be Modestly Undervalued.
Key valuation signals for ISX:KAEF:
ROE %: 16.64% (166300% above median its 10-year median of 0.01)
GF Value™: Rp581.98 vs. price of Rp456.00 (21.6% below fair value)
Industry Position: 134.4% above the Medical Distribution median (#94 of 113)
No single metric tells the full story. See the ISX:KAEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kimia Farma Tbk is an Indonesia-based company engaged in the production and distribution of healthcare products. It operates through the following segments: Manufacture, Distribution, Retail, and Others. The company provides its products in categories including OTC & Herb, Ethical, Cosmetic, Generic, and others. Some of its product offerings include Alergine, Kimoxil, Loprezol, Enkasari, and Batugin among others. It generates maximum revenue from the Retail segment.
56GF Score
Get the complete analysis for ISX:KAEF
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:KAEF has been successfully added to your 
